NETWORK PHARMACOLOGY-BASED INVESTIGATION OF CATECHIN, EPIGALLOCATECHIN, AND EPIGALLOCATECHIN GALLATE AGAINST BREAST AND LUNG CANCER
Main Article Content
Keywords
Catechin, epigallocatechin, epigallocatechin gallate, lung cancer, breast cancer
Abstract
Breast and lung cancers are complex diseases influenced by multiple factors, involving intricate molecular changes and disrupted signalling pathways. Catechin, epigallocatechin (EGC), and epigallocatechin gallate (EGCG) are flavan-3-ols found in nature that have shown potential in cancer treatment. This study focused on identifying shared molecular targets of these catechins in breast and lung cancers using a network pharmacology method. Information on targets related to catechin, EGC, and EGCG was sourced from the SWISS target prediction, PubChem database, while genes linked to breast and lung cancers were gathered from GeneCards. Common targets were pinpointed using Venny 2.1, and protein–protein interactions were analyzed using the STRING database.. A total of 101 targets related to compounds were discovered, alongside 21,768 genes linked to breast cancer and 24,525 genes associated with lung cancer. Through Venny analysis, three shared targets were identified: sclerostin (SOST), transthyretin (TTR), and tyrosinase (TYR). STRING analysis revealed that these three proteins do not directly interact under the specified interaction conditions. The functional interpretation highlighted connections with Wnt/bone-related signaling, processes associated with transthyretin, tyrosine metabolism, and melanogenesis. In summary, the results imply that catechin, EGC, and EGCG might engage with various molecular targets linked to breast and lung cancer. These findings offer initial mechanistic insights into the potential anticancer effects of the selected catechins and suggest the need for further experimental validation.
References
2.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
3.Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454.
4.Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea—a review. J Am Coll Nutr. 2006;25(2):79–99.
5.Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006;66(5):2500–2505.
6.Thangapazham RL, Passi N, Maheshwari RK. Green tea polyphenol and its chemopreventive and therapeutic effects on breast cancer. Cancer Lett. 2007;245(1–2):74–85.
7.Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807–1821.
8.Farabegoli F, Papi A, Orlandi M. (-)-Epigallocatechin-3-gallate: a review of its chemopreventive effects in breast cancer. Molecules. 2011;16(6):4731–4747.
9.Filippini T, Malavolti M, Borrelli F, et al. Green tea consumption and breast cancer risk: a systematic review and meta-analysis of observational studies. Nutrients. 2020.The broader evidence base indicates that epidemiological findings are mixed; a previous systematic review/meta-analysis found a modest reduction in breast cancer risk among women with higher green-tea consumption in case-control studies.
10.Seely D, Mills EJ, Wu P, Verma S, Guyatt GH. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: a systematic review and meta-analysis. Integr Cancer Ther. 2005;4(2):144–155.
11.Aggarwal V, Tuli HS, Tania M, et al. Molecular mechanisms of action of epigallocatechin gallate in cancer: recent trends and advancement. Semin Cancer Biol. 2022;80:256–275. doi:10.1016/j.semcancer.2020.05.011.
12.Mirbabaei Ghafghazi D, Sze NSK, Tsiani E. Effects of epigallocatechin gallate against lung cancer: mechanisms of action and therapeutic potential. Nutrients. 2026;18(3):378. doi:10.3390/nu18030378.
13.Tang N, Wu Y, Zhou B, Wang B, Yu R. Green tea, black tea consumption and risk of lung cancer: a meta-analysis. Lung Cancer. 2009;65(3):274–283. doi:10.1016/j.lungcan.2008.12.002.
14.Wang H, Zhou Y, Yu D, Zhu H, Wang J, et al. Tea consumption and lung cancer risk: a meta-analysis of case-control and cohort studies. Nutr Cancer. 2014.
15.Liu X, Wu WY, Jiang BH, Yang M, Guo DA. Pharmacological tools for the development of traditional Chinese medicine. Trends Pharmacol Sci. 2013;34(11):620–628. doi:10.1016/j.tips.2013.09.004.
16.Hulsen T, de Vlieg J, Alkema W. BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics. 2008;9:488. Venn-diagram approaches are widely used to visualize intersections between biological datasets.
17.Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613.
18.Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–D646
19.Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51(D1):D1373–D1380. doi:10.1093/nar/gkac956.
20.Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1.30.1–1.30.33. doi:10.1002/cpbi.5.
21.Safran M, Dalah I, Alexander J, Rosen N, Stein TI, Shmoish M, et al. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020. doi:10.1093/database/baq020.
22.Oliveros JC. Venny. An interactive tool for comparing lists with Venn's diagrams. Venny 2.1.0. BioinfoGP, CNB-CSIC.
23.Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131.
24. Szklarczyk D, Kirsch R, Koutrouli M, Nastou KC, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–D646. doi:10.1093/nar/gkac1000.
25. Hiraga T, Horibe K, Koide M, Yamashita T, Kobayashi Y. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells. Cancer Sci. 2023;114(6):2460–2470. doi:10.1111/cas.15765.
26. Hao S, Sun S, Xiao X, He D, Liu L. Selective expression of transthyretin in subtypes of lung cancer. J Mol Histol. 2016;47(3):239–247. doi:10.1007/s10735-016-9666-3.
27. Zhu Y, et al. Effect and mechanism of transthyretin over-expression on proliferation and cell cycle of lung cancer A549 cells. Iran J Public Health. 2021.
28. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51(D1):D1373–D1380. doi:10.1093/nar/gkac956.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
